Evidence map›Paper›PMID 31481130›Full record

ArticleActa neuropathologica communications2019

Encephalopathy induced by Alzheimer brain inoculation in a non-human primate.

Charlotte Gary, Suzanne Lam, Anne-Sophie Hérard, James E Koch, Fanny Petit, Pauline Gipchtein, Stephen J Sawiak, Raphaëlle Caillierez, Sabiha Eddarkaoui, Morvane Colin and 9 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Neurodegenerative Disease Tauopathies.Annual review of pathology · 2024
    Review
  13. Article
  14. Article
  15. Non-human primates in prion diseases.Cell and tissue research · 2023
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 3 countries.

Charlotte GaryCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.
Suzanne LamCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.
Anne-Sophie HérardCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.
James E KochCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.
Fanny PetitCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.
Pauline GipchteinCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.
Stephen J SawiakWolfson Brain Imaging Centre, University of Cambridge, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
Raphaëlle CaillierezLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Université de Lille, Inserm, CHU-Lille, UMR-S1172, Alzheimer & Tauopathies, Rue Polonovski, 59045, Lille, France.
Sabiha EddarkaouiLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Université de Lille, Inserm, CHU-Lille, UMR-S1172, Alzheimer & Tauopathies, Rue Polonovski, 59045, Lille, France.
Morvane ColinLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Université de Lille, Inserm, CHU-Lille, UMR-S1172, Alzheimer & Tauopathies, Rue Polonovski, 59045, Lille, France.
Fabienne AujardUMR7179 CNRS-MNHN, MECADEV (Adaptive Mechanisms and Evolution), 1 Avenue du Petit Château, 91800, Brunoy, France.
Jean-Philippe DeslysCommissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Institut François Jacob, SEPIA, Université Paris-Saclay, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.
French Neuropathology Network
Emmanuel BrouilletCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.
Luc BuéeLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Université de Lille, Inserm, CHU-Lille, UMR-S1172, Alzheimer & Tauopathies, Rue Polonovski, 59045, Lille, France.
Emmanuel E ComoyCommissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Institut François Jacob, SEPIA, Université Paris-Saclay, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.
Fabien PifferiUMR7179 CNRS-MNHN, MECADEV (Adaptive Mechanisms and Evolution), 1 Avenue du Petit Château, 91800, Brunoy, France.
Jean-Luc PicqCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.
Marc DhenainCentre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France. marc.dhenain@cea.fr.ORCID 0000-0001-8804-4101
Université Paris-Sud · FRInserm · FRCentre National de la Recherche Scientifique · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRUniversity of Cambridge · GB

Funding

Association France Alzheimer InductAlzCEA-Bottom-Up Is'AbetalzFondation Plan Alzheimer AmylNet
6 · The paper itself

Abstract

Alzheimer's disease is characterized by cognitive alterations, cerebral atrophy and neuropathological lesions including neuronal loss, accumulation of misfolded and aggregated β-amyloid peptides (Aβ) and tau proteins. Iatrogenic induction of Aβ is suspected in patients exposed to pituitary-derived hormones, dural grafts, or surgical instruments, presumably contaminated with Aβ. Induction of Aβ and tau lesions has been demonstrated in transgenic mice after contamination with Alzheimer's disease brain homogenates, with very limited functional consequences. Unlike rodents, primates naturally express Aβ or tau under normal conditions and attempts to transmit Alzheimer pathology to primates have been made for decades. However, none of earlier studies performed any detailed functional assessments. For the first time we demonstrate long term memory and learning impairments in a non-human primate (Microcebus murinus) following intracerebral injections with Alzheimer human brain extracts. Animals inoculated with Alzheimer brain homogenates displayed progressive cognitive impairments (clinical tests assessing cognitive and motor functions), modifications of neuronal activity (detected by electroencephalography), widespread and progressive cerebral atrophy (in vivo MRI assessing cerebral volume loss using automated voxel-based analysis), neuronal loss in the hippocampus and entorhinal cortex (post mortem stereology). They displayed parenchymal and vascular Aβ depositions and tau lesions for some of them, in regions close to the inoculation sites. Although these lesions were sparse, they were never detected in control animals. Tau-positive animals had the lowest performances in a memory task and displayed the greatest neuronal loss. Our study is timely and important as it is the first one to highlight neuronal and clinical dysfunction following inoculation of Alzheimer's disease brain homogenates in a primate. Clinical signs in a chronic disease such as Alzheimer take a long time to be detectable. Documentation of clinical deterioration and/or dysfunction following intracerebral inoculations with Alzheimer human brain extracts could lead to important new insights about Alzheimer initiation processes.

Indexed as

Alzheimer DiseaseAnimalsBrainBrain DiseasesCheirogaleidaeElectroencephalographyFemaleHumansMagnetic Resonance ImagingMaleMiceMice, TransgenicPrimatesSpecies SpecificityAlzheimer’s diseaseCerebral atrophyCognitive impairmentMicrocebus murinusMouseNeurodegenerative diseaseNeuronal functionPrionTau pathologyβ-Amyloid pathology

Identifiers

PMID31481130
PMCPMC6724379
OpenAlexW2971759903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.